Dr. Chari Discusses Carfilzomib Dosing in Myeloma

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.

The dose schedule, duration of infusion, and combination therapy are the most important factors to consider when using carfilzomib as a treatment for patients with myeloma, Chari says. At Mount Sinai, Chari says that every patient receiving carfilzomib is infused over 30 minutes, so there is no room for confusion of dosing versus time of infusion.

The drugs that are being given in combination with carfilzomib are also an important consideration, Chari says. Doses of carfilzomib beyond 56 mg should probably not be given in combination with immunomodulatory agents such as lenalidomide (Revlimid) and pomalidomide (Pomalyst), Chari cautions. Although, a dose of 70 mg should be safe with monoclonal antibodies, so the type of agent is important to consider, as well.